Celgene has kicked off pharma’s billion dollar M&A activity for the New Year with its $1.1 billion acquisition of Impact Biomedicines.
With the acquisition of Impact, Celgene gains access to fedratinib for the treatment of myelofibrosis and polycythemia vera.
As well as the upfront payment, the deal also includes up to $1.4 billion in contingent payments based on regulatory milestones for myelofibrosis.
Celgene will make payments depending on sales, with a maximum of $4.5 billion due if annual net sales of Impact’s treatments exceed $5 billion.
In all, the deal could be worth as much as $7 billion.